Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 12/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17376514 | 1.00 | FFAR2 (0.43) | FFAR2MAPTNPSR1MAPK1ALDH1A1 | |
| SCHEMBL17376487 | 0.84 | FFAR2 (0.45) | FFAR2MAPTNPSR1MAPK1ALDH1A1 | |
| SCHEMBL17376400 | 0.84 | FFAR2 (0.45) | FFAR2MAPTNPSR1MAPK1ALDH1A1 | |
| SCHEMBL17376582 | 0.84 | NPSR1 (0.36) | FFAR2MAPTNPSR1MAPK1ALDH1A1 | |
| SCHEMBL9126475 | 0.82 | ALDH1A1 (0.56) | MAPTNPSR1MAPK1ALDH1A1CYP1A2 | |
| SCHEMBL18946979 | 0.78 | FFAR2 (0.45) | FFAR2 | |
| SCHEMBL5773495 | 0.76 | HTT (0.52) | MAPTMAPK1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL17376417 | 0.76 | FFAR2 (0.42) | FFAR2MAPTNPSR1MAPK1ALDH1A1 | |
| SCHEMBL17376527 | 0.75 | FFAR2 (0.50) | FFAR2MAPTMAPK1ALDH1A1MEN1 | |
| SCHEMBL18919287 | 0.75 | FFAR2 (0.50) | FFAR2MAPTMAPK1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA CAMBRIDGE LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| EP-3160965-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015198045-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015198045-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059713-B2 | 3-substituted 2-amino-indole derivatives | NPY5R, XDH, NPY4R | FFAR2 2278/4885MAPT 3061/4885NPSR1 159/4885 |
| US-20170158700-A1 | 3-SUBSTITUTED 2-AMINO-INDOLE DERIVATIVES | NPY5R, XDH, NPY4R | FFAR2 2278/4885MAPT 3061/4885NPSR1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.